Loading company…
Paradox Immunotherapeutics develops antibodies targeting misfolded proteins linked to neurodegenerative diseases.
Paradox Immunotherapeutics develops monoclonal antibodies that target misfolded proteins associated with diseases including ALS, Alzheimer’s, and Parkinson’s. The company is based in Toronto, Canada, and was founded in 2019. In February 2025, it raised USD 10.00 mn in venture funding from SymBiosis Capital Management.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in